Evidence map›Paper›PMID 29634317›Full record

ArticleAssay and drug development technologies

Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction.

Jinglin Xiong, Valentina Gonzalez Pecchi, Min Qui, Andrey A Ivanov, Xiulei Mo, Qiankun Niu, Xiang Chen, Haian Fu, Yuhong Du

Open access · greenAbstract read
In one paragraph

Article in Assay and drug development technologies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS.Journal of molecular cell biology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Chemical Screening of Nuclear Receptor Modulators.International journal of molecular sciences · 2020
    Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jinglin Xiong1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Valentina Gonzalez Pecchi1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Min Qui1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Andrey A Ivanov1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Xiulei Mo1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Qiankun Niu1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Xiang Chen3 Department of Dermatology, Xiangya Hospital, Central South University , Changsha, China .
Haian Fu1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Yuhong Du1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
Emory University · USCentral South University · CNXiangya Hospital Central South University · CN

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
HIGH THROUGHPUT PROTEIN-PROTEIN INTERACTION INTERROGATION IN CANCERU01CA168449 · NCI · EMORY UNIVERSITY · PI FU, HAIAN · 2012 to 2016
$4.2M
NCI NIH HHS P30 CA138292NCI NIH HHS U01 CA168449
6 · The paper itself

Abstract

Epigenetic modulators play critical roles in reprogramming of cellular functions, emerging as a new class of promising therapeutic targets. Nuclear receptor binding SET domain protein 3 (NSD3) is a member of the lysine methyltransferase family. Interestingly, the short isoform of NSD3 without the methyltransferase fragment, NSD3S, exhibits oncogenic activity in a wide range of cancers. We recently showed that NSD3S interacts with MYC, a central regulator of tumorigenesis, suggesting a mechanism by which NSD3S regulates cell proliferation through engaging MYC. Thus, small molecule inhibitors of the NSD3S/MYC interaction will be valuable tools for understanding the function of NSD3 in tumorigenesis for potential cancer therapeutic discovery. Here we report the development of a cell lysate-based time-resolved fluorescence resonance energy transfer (TR-FRET) assay in an ultrahigh-throughput screening (uHTS) format to monitor the interaction of NSD3S with MYC. In our TR-FRET assay, anti-Flag-terbium and anti-glutathione S-transferase (GST)-d2, a paired fluorophores, were used to indirectly label Flag-tagged NSD3 and GST-MYC in HEK293T cell lysates. This TR-FRET assay is robust in a 1,536-well uHTS format, with signal-to-background >8 and a Z' factor >0.7. A pilot screening with the Spectrum library of 2,000 compounds identified several positive hits. One positive compound was confirmed to disrupt the NSD3/MYC interaction in an orthogonal protein-protein interaction assay. Thus, our optimized uHTS assay could be applied to future scaling up of a screening campaign to identify small molecule inhibitors targeting the NSD3/MYC interaction.

Indexed as

Fluorescence Resonance Energy TransferHigh-Throughput Screening AssaysHEK293 CellsHistone-Lysine N-MethyltransferaseHumansNuclear ProteinsProtein BindingProto-Oncogene Proteins c-mycTime FactorsHistone-Lysine N-MethyltransferaseNSD3 protein, humanNuclear ProteinsProto-Oncogene Proteins c-mycepigeneticsMYCNSD3protein–protein interactionscreeningTR-FRET

Identifiers

PMID29634317
PMCPMC5865254
OpenAlexW2795105261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.